Posters

      A mechanistic study of cigarette smoke-induced COPD in C57BL/6 mice: The impact of switching to pMRTP

      Veljkovic, E.; Phillips, B.; Peck, M. J.; Buettner, A.; Vuillaume, G.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Mar 23, 2014
      Conference name
      Society of Toxicology (SOT) 2014
      Link to more information
      Topic
      Summary

      In this study, the impact on the development of emphysema/COPD following inhalation of aerosol from two tobacco products, a reference cigarette (3R4F) and a prototypic modified risk tobacco product (pMRTP), was evaluated in C57BL/6 mice. The mice were exposed to an aerosol from 3R4F (750 µg/l TPM, 34.4 µg/l nicotine), pMRTP (nicotine concentration-matched) or filtered air (sham) for 4 hours per day, 5 days per week, up to 7 months. After 2 months of exposure to 3R4F, switching and cessation groups were exposed to pMRTP or filtered air, respectively. To analyze the progression of emphysema, evaluations of inflammation, pulmonary function, and various histopathological and molecular changes (transcriptomics and lipidomics) were performed at months 1, 2, 3, 4, 5 and 7. Exposure to 3R4F induced molecular, cellular and physiological modifications in lungs leading to emphysematous changes. Animals exposed to pMRTP exhibited negligible changes in all parameters assessed. Both cessation and switching groups showed a reversal of the inflammatory and functional responses induced by 3R4F smoke. Histopathological evaluation revealed a slowdown in the progression of emphysematous changes in switching and cessation groups. Smoking cessation or switching resulted in the rapid recovery at the transcription level. The lipid profiles in lung, liver and plasma similarly showed a clear 3R4F effect, with minimal changes associated with pMRTP exposure, and recovery near to sham-exposed levels following either switching or cessation. These data demonstrate that exposure to pMRTP for up to 7 months resulted in a response similar to fresh air-exposed animals using a battery of physiological and molecular measures. Furthermore, following a 2-month 3R4F cigarette smoke exposure period, both cessation and switching to a pMRTP aerosol resulted in the reversal or stabilization of parameters assessed.

      Related Publications

      Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System 2.2

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.